Safety and Feasibility of MR-guided Laser Thermal Ablation of Brain Lesions

Glioblastoma Clinical Trial

Official title:

Safety and Feasibility of MR-guided Laser Thermal Ablation of Brain Lesion Using the Tranberg® Thermal Therapy System and Tranberg® Thermoguide Workstation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05296122
• Other study ID #: CTP-2021-012
• Status: Recruiting
• Phase: N/A
• Start date: May 12, 2022
• Est. completion date: July 2025

Study information

• Verified date: February 2024
• Source: Clinical Laserthermia Systems AB
• Contact: Karin Peterson
• Phone: +46702690103
• Email: karin.peterson[@]clinicallaser.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This will be an open-label, pilot, exploratory, single centre clinical investigation. This is an early feasibility single arm study. No formal hypothesis is proposed. A total of up to 15 evaluable subjects receiving a non-radical ablation is planned. The safety and feasibility outcomes will be measured directly post-treatment, 48h and 3 months post-treatment. A minimal invasive neurosurgical approach with a Magnetic Resonance Imaging (MRI)-based stereotactic guidance system will be utilized for the planning, navigation, intracranial access, placement and confirmation of the Laser applicator prior to ablation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: July 2025
• Est. primary completion date: October 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Lesions eligible for Laser Interstitial ThermoTherapy (LITT), target tumor =10cc in volume

2. Age = 18 and < 80 years

3. Ability to undergo contrast-enhanced Computed Tomography (CT), Positron Emission Tomography (PET)-CT and contrast-enhanced MRI.

4. Women of childbearing potential must have a negative pregnancy test.

5. Eastern Cooperative Oncology Group (ECOG) performance status of =2

6. Primary glioblastoma/astrocytoma WHO grade IV confirmed by 1)Magnetic Resonance Imaging according to RANO citera and 2)Frozen section biosy diagnosis, and considered not suitable for open surgery or other primary treatment, or Recurrent glioblastoma/astrocytoma WHO grade IV confirmed by Magnetic Resonance Imaging according to RANO criteria.

7. =3 months since last radiotherapy of the brain

8. Supratentorial tumor localization with or without prior surgery for recurrence.

9. Life expectancy of =3 months

10. The subject reports having understood and has signed the Informed Consent Form (ICF) and is willing to comply with all investigation visits and assessments.

11. Anticipated compliance with treatment and follow-up

Exclusion Criteria:

1. Subject contraindicated for MRI, including subjects who may have contraindications due to implanted medical devices

2. Subject evaluated not to be fit for surgery due to liver/kidney/other organ dysfunction verified by laboratory tests

3. Identified intratumoral cystic or haemorrhagic transformation in target tumor

4. Known bleeding disorder

5. ECOG performance status of >2

6. Previous (within 30 days prior to enrollment / randomization) and concurrent treatment during the treatment phase with other investigational drug/s or device/s

7. Pregnancy or breastfeeding

8. The subject has a cognitive incapacity or language barrier precluding adequate understanding or cooperation

9. The subject is considered by the Investigator to be unsuitable to participate in the investigation for any other reason.

10. Any severe diseases interfering with the performance, evaluation, and outcome of the clinical evaluation

Related Conditions & MeSH terms

• Glioblastoma

Intervention

Device:
• TRANBERG® laser applicators when used in MR-guided laser thermal ablation of brain lesions using the TRANBERG® Thermal Therapy System and TRANBERG® Thermoguide Workstation.
The main purpose with the study is to investigate safety and feasibility of the TRANBERG® laser applicators when used in MR-guided laser thermal ablation of brain lesions using the TRANBERG® Thermal Therapy System and TRANBERG® Thermoguide Workstation together with SmartTwist™ MR Hand Drill with the SmartTip™ MR Drill Kit for MR-guided laser thermal ablation of brain lesions.

Locations

Country	Name	City	State
Sweden	Department of Neurosurgery, Skåne University Hospital	Lund

Sponsors (1)

Lead Sponsor	Collaborator
Clinical Laserthermia Systems AB

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Device performance	The volume of remaining tumor mass will be assessed by contrast enhanced MRI after MR-Guided laser thermal ablation using the TRANBERG® Thermal Therapy System and TRANBERG® Thermoguide Workstation.	At 3 months after treatment
Primary	Device and procedure related adverse events	The number and severity of adverse events related to the TRANBERG® Laser applicator when used in MR-guided laser thermal ablation of brain lesions	From Day 1 throughout the study until 3 months
Secondary	Device and procedure related adverse events	The number and severity of adverse events related to the SmartTwist™ MR HAND DRILL with the SmartTip™ MR Drill Kit when used for intracranial access.	From Day 1 throughout the study until 3 months